Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Researchers Pinpoint Potential Enzyme For T-Cell Leukemia Treatment

Researchers Pinpoint Potential Enzyme For T-Cell Leukemia Treatment

Researchers analyze how Topo II enzyme may affect stability of genomes

Researchers analyze how Topo II enzyme may affect stability of genomes

Australian researchers reveal how nutlins pave way for improving future of cancer treatment

Australian researchers reveal how nutlins pave way for improving future of cancer treatment

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

CHLA, Thermo Fisher Scientific agree to develop NGS-based panel for pediatric cancer research

CHLA, Thermo Fisher Scientific agree to develop NGS-based panel for pediatric cancer research

Mtss1 'tumour suppressor' for CML

Mtss1 'tumour suppressor' for CML

Asterias Biotherapeutics simplifies capital structure through previously announced Asset Swap with BioTime

Asterias Biotherapeutics simplifies capital structure through previously announced Asset Swap with BioTime

CTI BioPharma announces Q4 and FY 2015 earnings

CTI BioPharma announces Q4 and FY 2015 earnings

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

UAB research reveals heterogonous population of leukemia stem cells

UAB research reveals heterogonous population of leukemia stem cells

Research findings identify potential genetics-guided precision medicine for leukemia patients

Research findings identify potential genetics-guided precision medicine for leukemia patients

TUM researchers make progress in bringing immunotherapy to fight against cancer, infectious diseases

TUM researchers make progress in bringing immunotherapy to fight against cancer, infectious diseases

NCCN publishes new guidelines with NCCN Evidence Blocks for Breast, Colon, Kidney, and Rectal Cancers

NCCN publishes new guidelines with NCCN Evidence Blocks for Breast, Colon, Kidney, and Rectal Cancers

Study holds promise for new alternatives to treat leukemia

Study holds promise for new alternatives to treat leukemia

Researchers use hydrogel to prevent stem cells and human embryos from differentiating

Researchers use hydrogel to prevent stem cells and human embryos from differentiating

Pediatric ALL patients treated with chemotherapy alone at risk for neurocognitive deficits

Pediatric ALL patients treated with chemotherapy alone at risk for neurocognitive deficits

Some heart disease drugs, antibiotics show promising perspectives in treating cancers

Some heart disease drugs, antibiotics show promising perspectives in treating cancers

Abnormal breakage of chromosomes in white blood cells triggers aggressive form of ALL

Abnormal breakage of chromosomes in white blood cells triggers aggressive form of ALL

New personalized DNA-based digital assay has potential to dramatically impact CML management

New personalized DNA-based digital assay has potential to dramatically impact CML management

Bone loss linked with ALL therapy occurs during first month of treatment

Bone loss linked with ALL therapy occurs during first month of treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.